Trial Profile
A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients With Symptomatic Transthyretin Amyloid Cardiomyopathy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Nov 2022
Price :
$35
*
At a glance
- Drugs Acoramidis (Primary)
- Indications Amyloidosis; Cardiomyopathies
- Focus Proof of concept; Therapeutic Use
- Sponsors Eidos Therapeutics
- 18 Mar 2019 Results published in the Media Release
- 18 Mar 2019 According to an Eidos Therapeutics media release, subgroup analyses data from this trial presented at American College of Cardiology (ACC) Scientific Sessions 2019.
- 18 Mar 2019 According to an Eidos Therapeutics media release, data from this trial published in the Journal of the American College of Cardiology (JACC) 2019.